OakChart

Moleculin Biotech Inc

MBRXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

8.060.00 (0.00%)
2026-11-11 22:15 CET
Market cap
8.46 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-32.52 USD m
Free cash flow, TTM
-25.36 USD m
EPS diluted, TTM
-342.74
P/E
-
Compare

Price

MBRX against its 20, 50 and 200-day averages
2050200beatmiss
0.0050.00100.00150.00483K966KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MBRXclose 8.0620-day 7.6150-day 10.17200-day 37.128.06

96.8% under the 52-week high of 253.05 on 12 Nov 2025. 52-week low 3.23 on 3 Aug 2026. Last 15 sessions, 87.5% high to low

Volume 0.30× normal · the line is the 50-bar volume average

Profile

MBRX
52-week range, 2% of the way up
3.23253.05

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Employees17
IPOJun 02, 2016
Beta2.07
ATR, 14d0.97
Rel volume0.30
Short float5.80%
Insider own10.67%
Inst own7.81%

Snapshot

6 groups

Valuation

Index-
Market Cap8.46M
Enterprise Value1.49M
Income-32.52M
Sales0.00M
Book/sh32.64
Cash/sh6.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOJun 02, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.25
P/C1.17
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.94
Current Ratio0.94
Debt/Eq0.03
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-342.74
EPS next Y-23.40
EPS next Q-8.87
EPS this Y88.51%
EPS next Y64.18%
EPS next 5Y64.05%
EPS past 3/5Y57.89% 46.71%
Sales past 3/5Y- -
EPS Y/Y TTM85.06%
Sales Y/Y TTM-
EPS Q/Q88.60%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.9.87% -

Ownership

Insider Own10.67%
Insider Trans0.00%
Inst Own7.81%
Inst Trans-
ROA-142.11%
ROE-1371.64%
ROIC-258.45%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA205.91%
SMA50-20.75%
SMA200-78.29%
Trades-

Technical

Shs Outstand1.05M
Shs Float0.94M
Short Float5.80%
Short Ratio1.18
Short Interest0.05M
52W High253.05 -96.81%
52W Low3.23 149.69%
Volatility8.39% 13.64%
ATR (14)0.97
RSI (14)45.03
Beta2.07
Rel Volume0.30
Avg Volume46.08K
Volume14,035

Performance

Perf Week-4.73%
Perf Month-7.40%
Perf Quarter-29.46%
Perf Half Y-81.17%
Perf YTD-87.82%
Perf Year-96.63%
Perf 3Y-99.80%
Perf 5Y-99.96%
Perf 10Y-99.99%
Recom1.00
Target Price240.00
Prev Close8.06
Price8.06
Change %0.00%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Jun 09, 2025ResumedHH.C. WainwrightBuy$4-50.4%
Feb 12, 2025DowngradeMMaxim GroupBuy → Hold
Jul 18, 2022ResumedOOppenheimerOutperform$14+73.7%

Peers

Mkt cap
TickerCompanyMkt cap
CNSPCns Pharmaceuticals Inc5.75M
ATNMActinium Pharmaceuticals Inc49.99M
GTBPGT Biopharma Inc8.12M
KURAKura Oncology Inc687.66M
SNTISenti Biosciences Holdings Inc4.90M
SNDXSyndax Pharmaceuticals Inc863.37M
JAZZJazz Pharmaceuticals plc15.93B
RIGLRigel Pharmaceuticals838.31M
CLRBCellectar Biosciences Inc11.44M
KPTIKaryopharm Therapeutics Inc0.39M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies (GlobeNewswire) -6.93%
  • Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
  • Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 (GlobeNewswire) -9.40%
  • Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial (GlobeNewswire) +16.79%
  • Moleculin Announces Reverse Stock Split (GlobeNewswire) -24.24%
  • Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit (GlobeNewswire)
  • Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout (GlobeNewswire) -7.49%
  • Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine (GlobeNewswire) -5.42%
  • Annamycin Turns "Cold" Pancreatic Tumors "Hot" in New Preclinical Data Presented at AACR (GlobeNewswire) +6.12%
  • Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 (GlobeNewswire) -6.57%
  • Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings (GlobeNewswire) +8.42%
  • Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand (GlobeNewswire) -13.85%
  • Moleculin CEO, Walter Klemp, Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire) +14.78%
  • Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial (GlobeNewswire) +7.16%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-28.000-31.067-28.0000.000.003
2026Q12026-05-15-70.800-46.666-70.8450.000.003
2025Q42026-03-1952.266-122.2796.5730.000.003
2025Q32025-11-17-340.33-131.67-340.430.000.003
2025Q22025-08-13-245-215-246.040.000.003
2025Q12025-05-13-345-277.5-344.40.000.002
2024Q42025-03-24125-641.65-278.50.000.003
2024Q32024-11-08-1,425-1,220-1,4260.000.001
2024Q22024-08-14-850-1,255-849.110.000.002
2024Q12024-05-10-1,010-1,765-1,0080.000.002
2023Q42024-03-22-2,510-1,613-2,5630.000.004
2023Q32023-11-13-1,425-1,675-1,4110.000.003
2023Q22023-08-11-1,500-2,050-1,5100.000.003
2023Q12023-05-11-2,100-2,125-2,0650.000.003
2022Q42023-03-24-1,725-2,275-1,7740.000.003
2022Q32022-11-10-2,250-2,075-2,2560.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-14,399-17,100-14,5930.000.00
2020FY-13,199-16,350-13,2200.000.00
2021FY-6,295-5,813-4,4350.000.00
2022FY-7,575-8,225-7,6100.000.00
2023FY-7,535-6,581-7,5340.000.00
2024FY-3,160-3,802-3,7830.000.00
2025FY-568.4-727-568.40.000.00
2026FY--65.333--0.00
2027FY--23.400--0.00
2028FY--26.400---
2029FY-6.700--51.99
2030FY-42.300--121.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-08-032000.000.000.00
2026Q3S2026-06-271000.000.000.00
2026Q3S2026-05-152000.000.000.00
2026Q3S2026-03-232000.000.000.00
2026Q3S2026-03-191000.000.000.00
2026Q3S2026-02-201000.000.000.00
2026Q3R2026-10-28100-6.80-6.80-6.80
2026Q3R2026-08-14110-6.80-6.80-6.80
2026Q3R2026-06-30110-19.20-19.20-19.20
2026Q3R2026-05-18100-21.00-21.00-21.00
2026Q3R2026-05-15110-21.00-21.00-21.00
2026Q3R2026-03-19110-21.00-21.00-21.00
2026Q3R2026-03-04110-21.00-21.00-21.00

Estimate history

EPS, annual-23761.35-20630.7-14592.6-13220.1-4435.35-7610.25-7534.125-3782.75-568.376-342.7408
Period201720182019202020212022202320242025TTM
EPS, quarterly-849.11-1425.85-278.495-344.4-246.035-340.4396.573-70.845-28.039
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00.0010.0010.0020.0040.0040.0040.0070.160.355
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0050.0060.0070.0280.060.0990.160.2670.355
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.050.090.130.130.220.260.280.180.07
Gross Profit-0.05-0.09-0.13-0.13-0.22-0.26-0.28-0.18-0.07
Selling, General and Administrative Excl. Other28.8325.0126.5229.5030.4222.7119.4617.3414.96
Research and Development19.6815.8917.7319.4918.9714.4212.7611.019.73
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-28.87-25.10-26.64-29.63-30.64-22.97-19.74-17.52-15.03
Interest Expense0.080.000.000.000.000.000.000.000.00
Unusual Expense-14.348.540.001.04-1.33-6.73-2.35-4.06-
Net Income Before Taxes-30.33-33.56-26.05-29.77-29.02-15.89-17.36-13.43-11.88
Income Taxes0.000.000.000.000.000.000.00-0.230.00
Consolidated Net Income-30.33-33.56-26.05-29.77-29.02-15.89-17.36-13.21-11.88
Net Income From Continuing Operations-30.33-33.56-26.05-29.77-29.02-15.89-17.36-13.21-11.88
Net Income-32.52-33.66-26.05-29.77-29.02-15.89-17.36-13.21-11.88
EPS (Recurring)-149.85-467.42-3,782.75-7,349.17-7,855.30-5,749.64-14,471.24-17,734.60-20,630.66
EPS (Basic, Before Extraordinaries)-342.74-568.38-3,782.75-7,534.12-7,610.25-4,435.35-13,220.10-14,592.60-20,630.70
EPS (Diluted)-342.74-568.38-3,782.75-7,534.12-7,610.25-4,435.35-13,220.10-14,592.60-20,630.70
EBITDA-28.83-25.01-26.52-29.50-30.42-22.71-19.46-17.34-14.96
Non-Operating Income (Expense)-15.720.090.590.910.280.350.040.03-0.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.581.661.731.982.272.371.681.121.14
Shares Outstanding0.350.160.010.000.000.000.000.000.00
Market Capitalization8.468.465.7425.5930.3553.1655.1841.8529.67

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.020.030.030.030.03
Gross Profit-0.01-0.01-0.01-0.02-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other7.557.877.525.885.695.916.617.10
Research and Development5.455.385.123.743.603.444.464.93
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.56-7.87-7.53-5.91-5.72-5.94-6.64-7.13
Interest Expense0.080.000.000.000.000.000.000.00
Unusual Expense0.01-10.77-23.1319.55-9.61-9.05-4.701.73
Net Income Before Taxes-7.63-12.8515.55-25.40-7.64-6.44-1.88-10.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.63-12.8515.55-25.40-7.64-6.44-1.88-10.59
Net Income From Continuing Operations-7.63-12.8515.55-25.40-7.64-6.44-1.88-10.59
Net Income-7.96-14.6115.45-25.40-7.64-6.44-1.88-10.59
EPS (Recurring)-28.02-107.40-4.63-157.02-462.64-683.55-765.55-1,263.02
EPS (Basic, Before Extraordinaries)-28.04-70.8596.57-340.43-246.03-344.40-278.50-1,425.85
EPS (Diluted)-28.04-70.8596.57-340.43-246.03-344.40-278.50-1,425.85
EBITDA-7.55-7.87-7.52-5.88-5.69-5.91-6.61-7.10
Non-Operating Income (Expense)0.01-15.74-0.040.06-11.53-9.550.06-1.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.440.380.460.300.420.480.430.35
Shares Outstanding0.350.270.160.100.060.030.010.01
Market Capitalization8.4612.2210.5926.239.1213.755.748.53

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.884.2823.5543.1570.9015.1710.737.137.71
Short Term Receivables0.010.020.100.020.040.000.010.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.800.902.622.431.552.022.740.840.59
Total Current Assets9.695.1926.2745.6072.5017.2013.487.978.30
Net Property, Plant & Equipment0.390.580.800.680.450.690.600.460.03
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable----0.000.13---
Intangible Assets11.1511.1511.1511.1511.1511.1511.1511.1511.15
Other Assets0.900.000.000.000.000.000.000.000.00
Total Assets22.1316.9338.2257.4284.0929.1625.2319.5919.48
Short Term Debt Incl. Current Port. of LT Debt0.140.120.100.120.100.120.100.000.00
Accounts Payable3.512.032.502.101.361.132.151.250.00
Other Current Liabilities3.213.214.222.612.161.671.312.632.21
Total Current Liabilities6.855.366.824.823.622.923.573.882.21
Long Term Debt0.220.360.470.340.060.160.280.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.040.004.860.081.418.195.821.440.15
Total Liabilities7.125.7212.145.235.1011.279.665.312.37
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.0111.2126.0752.1978.9917.8915.5714.2717.12
Total Shareholders Equity15.0111.2126.0752.1978.9917.8915.5714.2717.12
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity15.0111.2126.0752.1978.9917.8915.5714.2717.12
Total Liabilities & Stockholders Equity22.1316.9338.2257.4284.0929.1625.2319.5919.48
Book Value Per Share93.811,658.545,852.4813,673.1520,730.6511,629.6315,323.2122,512.1035,879.92
Tangible Book Value Per Share24.128.883,350.1410,752.5617,805.014,382.324,352.614,927.6812,513.33
Full-Time Employees1717181921151698
Price to Book Ratio0.250.960.730.520.673.082.692.082.08
Return on Assets-171.88-94.48-62.25-41.02-28.07-63.81-58.92-60.80-54.66
Return on Equity-319.85-139.74-76.07-44.25-32.81-103.74-88.50-75.67-61.13
Return on Invested Capital-220.38-225.21-112.14-55.26-20.10-96.16-83.33-83.21-57.28
Quick Ratio1.410.973.869.4620.025.893.782.063.75
Current Ratio1.410.973.869.4620.025.893.782.063.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-39.96-33.56-26.05-29.77-29.02-15.89-17.36-13.21-11.88
Depreciation0.050.090.130.130.220.260.280.180.07
Other Funds (Non Cash)12.5710.181.833.920.94-4.36-0.66-2.04-2.00
Funds from Operations-27.35-23.29-24.09-25.72-27.86-19.99-17.73-15.06-13.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.990.560.231.620.221.04-0.04-2.141.61
Cash from Operating Activities-25.36-22.73-23.86-24.10-27.64-18.95-17.77-17.20-12.20
Capital Expenditures0.000.00-0.01-0.12-0.07-0.02-0.38-0.05-0.42
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.01-0.12-0.07-0.02-0.37-0.05-0.42
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock25.0927.294.664.170.0074.7522.5720.8512.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock25.0927.294.664.170.0074.7522.5720.8512.04
Proceedsfrom Stock Options20.7625.774.664.170.0074.6822.5619.2912.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.01-0.030.48-0.02-0.02-0.020.000.00
Other Financing Activities Uses-0.01-0.01-0.03-0.03-0.02-0.02-0.020.000.00
Cash from Financing Activities25.0927.284.634.65-0.0274.7222.5520.8512.04
Exchange Rate Effect-0.030.05-0.03-0.02-0.03-0.020.03-0.00-0.01
Net Change in Cash-0.294.60-19.27-19.59-27.7655.734.443.60-0.58
Free Cash Flow-25.36-22.73-23.88-24.23-27.71-18.97-18.15-17.25-12.62
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.2610.328.886.707.567.72
Short Term Receivables0.000.010.010.010.010.01
Inventories0.000.000.000.000.000.00
Other Current Assets1.460.640.801.181.511.62
Total Current Assets8.7210.969.697.889.089.34
Net Property, Plant & Equipment0.320.350.390.420.470.53
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets11.1511.1511.1511.1511.1511.15
Other Assets0.900.900.900.900.900.00
Total Assets21.0923.3622.1320.3521.5921.01
Short Term Debt Incl. Current Port. of LT Debt0.140.140.140.130.130.12
Accounts Payable4.344.573.512.123.722.71
Other Current Liabilities4.833.253.213.434.064.07
Total Current Liabilities9.317.966.855.687.916.90
Long Term Debt0.150.180.220.260.290.33
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.040.030.0441.3320.5513.75
Total Liabilities9.508.187.1247.2728.7620.97
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity11.5915.1815.01-26.92-7.170.04
Total Shareholders Equity11.5915.1815.01-26.92-7.170.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.5915.1815.01-26.92-7.170.04
Total Liabilities & Stockholders Equity21.0923.3622.1320.3521.5921.01
Book Value Per Share32.6456.9093.81-271.93-118.601.49
Tangible Book Value Per Share1.2415.1224.12-384.54-303.12-393.06
Full-Time Employees--17---
Price to Book Ratio0.250.800.71-0.97-1.27327.49
Return on Assets-142.11-136.70-122.52-189.07-112.58-89.59
Return on Equity-1,371.64-398.45-228.00--503.80-214.79
Return on Invested Capital-65.07-83.58102.13---1,748.91
Quick Ratio0.941.381.411.391.151.35
Current Ratio0.941.381.411.391.151.35

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.63-12.8515.55-35.04-7.64-6.44
Depreciation0.010.010.010.020.030.03
Other Funds (Non Cash)0.295.59-22.8129.492.371.14
Funds from Operations-7.33-7.24-7.25-5.53-5.25-5.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.681.131.88-1.70-0.340.71
Cash from Operating Activities-6.66-6.11-5.37-7.22-5.58-4.56
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock3.617.617.506.385.428.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.617.617.506.385.428.00
Proceedsfrom Stock Options0.807.6125.77-13.415.428.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.010.000.000.00
Other Financing Activities Uses0.000.00-0.010.000.000.00
Cash from Financing Activities3.617.617.496.385.428.00
Exchange Rate Effect-0.01-0.060.05-0.010.000.00
Net Change in Cash-3.061.442.17-0.85-0.163.44
Free Cash Flow-6.66-6.11-5.37-7.22-5.58-4.56

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.80%0.1M0.9M72.47K
2026-10-150.67%0.0M0.9M63.97K
2026-09-301.11%0.0M0.9M63.86K
2026-09-151.63%0.0M0.9M65.72K
2026-08-311.01%0.0M0.9M61.51K
2026-08-142.46%0.0M0.6M58.47K
2026-07-3122.41%0.1M0.4M42.62K
2026-07-1519.94%0.1M0.3M25.67K
2026-06-3026.72%0.1M0.3M23.99K
2026-06-1521.83%0.1M0.3M8.83K
2026-05-2915.67%0.0M0.3M8.19K
2026-05-159.98%0.0M0.3M9.66K
2026-04-306.32%0.0M0.3M8.10K
2026-04-154.58%0.0M0.2M8.00K
2026-03-313.76%0.0M0.2M8.61K
2026-03-133.62%0.0M0.2M14.00K
2026-02-276.31%0.0M0.2M16.67K
2026-02-1314.57%0.0M0.2M13.99K
2026-01-3014.16%0.0M0.2M14.82K
2026-01-1511.78%0.0M0.2M15.70K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-308-KCurrent report2026-10-30SEC
2026-10-208-KCurrent report2026-10-16SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-10-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-098-KCurrent report2026-10-09SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-258-KCurrent report2026-09-25SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-188-KCurrent report2026-09-15SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-25SCHEDULE 13DSEC
2026-08-25SCHEDULE 13DSEC
2026-08-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-09SEC
2026-08-21424B5SEC
2026-08-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-09SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-10SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.79%
VANGUARD FIDUCIARY TRUST CO0.56%
GEODE CAPITAL MANAGEMENT, LLC0.51%
XTX Topco Ltd0.43%
MORGAN STANLEY0.38%
Rockefeller Capital Management L.P.0.28%
Tower Research Capital LLC0.07%
CITIGROUP INC0.05%
BARCLAYS PLC0.01%
BlackRock, Inc.0.01%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.53%
Fidelity Extended Market Index Fund0.29%
Fidelity Series Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.02%
Fidelity Total Market Index Fund0.00%

OakChart. MBRX. Cached 15 minutes.

Some panels did not load: insider.